sellWeak cluster of 410b5-1 plan
Charles McWherter sold $207k of CBAY
President of R&D at CymaBay Therapeutics, Inc.. 11,342 shares at an average of $18.28, traded Nov 17, 2023, filed Nov 17, 2023.
Warning score
22Value
$207k
11,342 shares
Holdings after
15,000
-43% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RolePresident
- +12Trade size$207k at market
- +10Share of holdings soldSold 43% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001062993-23-021139, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2023 | MOption exercise Common Stock | +11,342 | $5.00 | $57k | 26,342 | Nov 17, 2023 |
| Nov 17, 2023 | SOpen-market sale Common Stock10b5-1 | -11,342 | $18.28 | $207k | 15,000 | Nov 17, 2023 |
| Nov 17, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -708 | $0.00 | $0 | 704 | Nov 17, 2023 |
| Nov 17, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -236 | $0.00 | $0 | 234 | Nov 17, 2023 |
| Nov 17, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -3,892 | $0.00 | $0 | 3,890 | Nov 17, 2023 |
| Nov 17, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -6,506 | $0.00 | $0 | 6,504 | Nov 17, 2023 |
Related signals
Other insiders at CymaBay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $192k 6,000 shares | -100% | |
| 37Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $436k 18,403 shares | -107% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $118k 5,000 shares | -100% | |
| 28Weak | CymaBay Therapeutics, Inc. | Daniel Menold Vice President, Finance | $236k 10,000 shares | -100% | |
| 26Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $143k 6,000 shares | -100% | |
| 33Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $243k 11,332 shares | -57% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $110k 5,000 shares | -100% | |
| 32Weak | CymaBay Therapeutics, Inc. | Daniel Menold Vice President, Finance | $473k 21,497 shares | -215% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $120k 6,000 shares | -100% | |
| 40Moderate | CymaBay Therapeutics, Inc. | Sujal Shah Chief Executive Officer | $1.3M 64,865 shares | -28% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.